In a study of pembrolizumab in the treatment of PD-L1-positive patients with advanced GC, 53% of patients had tumor regression, 22% achieved partial remission imaging, and the safety was better than second-line chemotherapy [30]. This evidence concerns the gene CD274 and gastric cancer.